Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Rohrberg KS, Lopez JS, Milhem MM, Blank CU, Reijers I, Thistlethwaite F, Plummer R, Piha-Paul SA, Jänne PA, Shum E, Shaw HM, Debruyne PR, Lao C, Baurain JF, Choe JH, Gort E, Zhao Y, Jerusalem G, Schöffski P, Chen AW, Cohen EA, Mankowski WC, Roshkovan L, Katz SI, Kontos D, Brady LK, Qutaish M, Castro PG, Pencheva N, Bajaj G, Fu Y, Windfeld K, Reiter P, Jure-Kunkel M, Higgs BW, Amiri KI, Ahmadi T, Forssmann U, Ramalingam SS, Vergote I

Open source

DOI: 10.1158/2767-9764.crc-25-0359
Published: 2025 Nov 1
Container: Cancer research communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2767-9764.crc-25-0359,
  title = {Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.},
  author = {Rohrberg KS and Lopez JS and Milhem MM and Blank CU and Reijers I and Thistlethwaite F and Plummer R and Piha-Paul SA and Jänne PA and Shum E and Shaw HM and Debruyne PR and Lao C and Baurain JF and Choe JH and Gort E and Zhao Y and Jerusalem G and Schöffski P and Chen AW and Cohen EA and Mankowski WC and Roshkovan L and Katz SI and Kontos D and Brady LK and Qutaish M and Castro PG and Pencheva N and Bajaj G and Fu Y and Windfeld K and Reiter P and Jure-Kunkel M and Higgs BW and Amiri KI and Ahmadi T and Forssmann U and Ramalingam SS and Vergote I},
  year = {2025},
  journal = {Cancer research communications},
  doi = {10.1158/2767-9764.crc-25-0359},
  url = {https://doi.org/10.1158/2767-9764.crc-25-0359}
}

RIS

TY  - JOUR
TI  - Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
AU  - Rohrberg KS
AU  - Lopez JS
AU  - Milhem MM
AU  - Blank CU
AU  - Reijers I
AU  - Thistlethwaite F
AU  - Plummer R
AU  - Piha-Paul SA
AU  - Jänne PA
AU  - Shum E
AU  - Shaw HM
AU  - Debruyne PR
AU  - Lao C
AU  - Baurain JF
AU  - Choe JH
AU  - Gort E
AU  - Zhao Y
AU  - Jerusalem G
AU  - Schöffski P
AU  - Chen AW
AU  - Cohen EA
AU  - Mankowski WC
AU  - Roshkovan L
AU  - Katz SI
AU  - Kontos D
AU  - Brady LK
AU  - Qutaish M
AU  - Castro PG
AU  - Pencheva N
AU  - Bajaj G
AU  - Fu Y
AU  - Windfeld K
AU  - Reiter P
AU  - Jure-Kunkel M
AU  - Higgs BW
AU  - Amiri KI
AU  - Ahmadi T
AU  - Forssmann U
AU  - Ramalingam SS
AU  - Vergote I
PY  - 2025
JO  - Cancer research communications
DO  - 10.1158/2767-9764.crc-25-0359
UR  - https://doi.org/10.1158/2767-9764.crc-25-0359
ER  -

APA

KS, R., JS, L., MM, M., CU, B., I, R., F, T., R, P., SA, P., PA, J., E, S., HM, S., PR, D., C, L., JF, B., JH, C., E, G., Y, Z., G, J., P, S., AW, C., EA, C., WC, M., L, R., SI, K., D, K., LK, B., M, Q., PG, C., N, P., G, B., Y, F., K, W., P, R., M, J., BW, H., KI, A., T, A., U, F., SS, R., & I, V. (2025). Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.. Cancer research communications. https://doi.org/10.1158/2767-9764.crc-25-0359

Source records

pubmed · retrieved 2026-09-26T17:36:20.999Z